FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

T Matthews

Research Profile

Living Beings

HIV-1

Chemicals & Drugs

Concepts & Ideas

Molecular Sequence Data

Genes & Molecular Sequences

Amino Acid Sequences

Disorders

Procedures

Physiology

Cell Fusion

Phenomena

Circular Dichroism

Co-author Network

Publications

TOP 3
Thomas G Evans; M Juliana McElrath; T Matthews; David Montefiori; Kent J Weinhold; Mark Wolff; Michael C Keefer; Esper Kallas; Lawrence Corey; Geoffrey J Gorse; Robert B Belshe; Barney S Graham; Paul Spearman; David H Schwartz; Mark MULLIGAN; Paul A Goepfert; Patricia Fast; Phillip W. Berman; M Powell; D Francis
QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans.
M Juliana McElrath; Lawrence Corey; David Montefiori; Mark Wolff; David H Schwartz; Michael C Keefer; Robert B Belshe; Barney S Graham; T Matthews; P Wright; Geoffrey J Gorse; Raphael Dolin; Phillip W. Berman; D Francis; AM Duliege; Dani P Bolognesi; Donald Stablein; N Ketter; Patricia Fast
A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group.
Donald P Francis; TJ Gregory; M Juliana McElrath; Robert B Belshe; Geoffrey J Gorse; Sricharoen Migasena; Dwip Kitayaporn; P Pitisuttitham; T Matthews; David H Schwartz; Phillip W. Berman
Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of T Matthews (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2001: Thomas G Evans; M Juliana McElrath; T Matthews; David Montefiori; Kent J Weinhold; Mark Wolff; Michael C Keefer; Esper Kallas; Lawrence Corey; Geoffrey J Gorse; Robert B Belshe; Barney S Graham; Paul Spearman; David H Schwartz; Mark MULLIGAN; Paul A Goepfert; Patricia Fast; Phillip W. Berman; M Powell; D Francis
QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans.
Vaccine 2001;19(15-16):2080-91.
2000: M Juliana McElrath; Lawrence Corey; David Montefiori; Mark Wolff; David H Schwartz; Michael C Keefer; Robert B Belshe; Barney S Graham; T Matthews; P Wright; Geoffrey J Gorse; Raphael Dolin; Phillip W. Berman; D Francis; AM Duliege; Dani P Bolognesi; Donald Stablein; N Ketter; Patricia Fast
A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group.
AIDS research and human retroviruses 2000;16(9):907-19.
1998: Donald P Francis; TJ Gregory; M Juliana McElrath; Robert B Belshe; Geoffrey J Gorse; Sricharoen Migasena; Dwip Kitayaporn; P Pitisuttitham; T Matthews; David H Schwartz; Phillip W. Berman
Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3.
AIDS research and human retroviruses 1998;14 Suppl 3():S325-31.
1998: Lawrence Corey; M Juliana McElrath; Kent J Weinhold; T Matthews; Donald Stablein; B Graham; Michael C Keefer; David H Schwartz; Geoffrey J Gorse
Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group.
The Journal of infectious diseases 1998;177(2):301-9.
1996: Phillip W. Berman; Krishna K Murthy; T Wrin; JC Vennari; E K Cobb; D J Eastman; M Champe; G R Nakamura; D Davison; M F Powell; J Bussiere; D P Francis; T Matthews; T J Gregory; J F Obijeski
Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1.
The Journal of infectious diseases 1996;173(1):52-9.
1995: M Girard; B Meignier; Françoise Barré-Sinoussi; Marie Paule Kieny; T Matthews; E Muchmore; P L Nara; Q Wei; Laurence Rimsky; Kent J Weinhold
Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1.
Journal of virology 1995;69(10):6239-48.
1995: C Wild; T Greenwell; D Shugars; L Rimsky-Clarke; T Matthews
The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure.
AIDS research and human retroviruses 1995;11(3):323-5.
1994: C Wild; J W Dubay; T Greenwell; T Baird; Terrence G Oas; C McDanal; Eric Hunter; T Matthews
Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(26):12676-80.
1994: David H Schwartz; U Sharma; M Busch; Kent J Weinhold; T Matthews; J Lieberman; D Birx; H Farzedagen; Joseph B Margolick; Thomas C Quinn
Absence of recoverable infectious virus and unique immune responses in an asymptomatic HIV+ long-term survivor.
AIDS research and human retroviruses 1994;10(12):1703-11.
1994: Robert B Belshe; Barney S Graham; Michael C Keefer; Geoffrey J Gorse; P Wright; Raphael Dolin; T Matthews; Kent J Weinhold; Dani P Bolognesi; R Sposto
Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.
JAMA : the journal of the American Medical Association 1994;272(6):475-80.
1993: C Wild; T Greenwell; T Matthews
A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion.
AIDS research and human retroviruses 1993;9(11):1051-3.
1992: C Wild; Terrence G Oas; C McDanal; Dani P Bolognesi; T Matthews
A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(21):10537-41.
1990: F Celada; C Cambiaggi; J Maccari; Samuele E Burastero; T Gregory; E Patzer; J Porter; C McDanal; T Matthews
Antibody raised against soluble CD4-rgp120 complex recognizes the CD4 moiety and blocks membrane fusion without inhibiting CD4-gp120 binding.
The Journal of experimental medicine 1990;172(4):1143-50.
1990: S D Putney; J Rusche; K Javaherian; T Matthews; Dani P Bolognesi
Structural and functional features of the HIV envelope glycoprotein and considerations for vaccine development.
Biotechnology (Reading, Mass.) 1990;14():81-110.
1989: Phillip W. Berman; L Riddle; G Nakamura; O K Haffar; W M Nunes; P Skehel; R Byrn; J Groopman; T Matthews; T Gregory
Expression and immunogenicity of the extracellular domain of the human immunodeficiency virus type 1 envelope glycoprotein, gp160.
Journal of virology 1989;63(8):3489-98.
1986: A J Nahmias; J Weiss; X Yao; F Lee; R Kodsi; M Schanfield; T Matthews; Dani P Bolognesi; D Durack; A Motulsky
Evidence for human infection with an HTLV III/LAV-like virus in Central Africa, 1959.
Lancet 1986;1(8492):1279-80.